#United States #Singapore #ChemT Biotechnology #CelMo #Chemplify

ChemT Biotechnology Secures $5 Million Funding

ChemT Biotechnology, a pioneering AI-driven biotech firm, has achieved a significant milestone by raising $5 million in funding over 18 months. This accomplishment includes a notable seed round of $4 million, which was spearheaded by Wavemaker Ventures and supported by various esteemed investors from the United States and Asia, including SEEDS and Temasek Life Sciences Accelerator.

Addressing Biomanufacturing Challenges

The biotech landscape faces substantial hurdles in producing biologics at scale. Traditional manufacturing methods are often marred by prolonged development timelines, unpredictable yields, and high costs, ultimately delaying patient access to critical treatments. ChemT identifies a lack of precise methodologies in manipulating cells—the essential units for biologics manufacturing—as the core issue.

Unlike standard AI drug discovery and lab automation firms, ChemT has taken to integrate intelligence directly into the manufacturing process. Through this innovative approach, the company aims to enhance the understanding of cellular behavior in biomanufacturing. This shift not only helps in accelerating production but also improves reliability and scalability.

CelMo™: The Virtual Cell Platform

At the center of ChemT's technological advancements is CelMo™, its AI-driven Virtual Cell platform. This cutting-edge tool is trained on an extensive dataset of biological sequencing reads, enabling it to simulate cell responses to various manufacturing conditions, genetic modifications, and other external stresses.

The simulation capabilities of CelMo™ allow for an in-depth analysis of cell behavior during manufacturing processes. By monitoring the activation and suppression of different biological functions—including growth, metabolism, stress response, and productivity—CelMo™ generates a comprehensive dynamic picture of cellular states throughout production.

With these insights, ChemT can design specific small molecules that guide cell behavior improving manufacturing performance. Early results have shown remarkable success; particularly in CHO cells, which are frequently used for producing therapeutic proteins, CelMo™ has achieved a 50% uptick in antibody production and a remarkable 40% decrease in production timelines.

Chemplify™ and Market Expansion

ChemT's flagship product, Chemplify™, employs a similar approach tailored for T-cell manufacturing, which is crucial for advanced cancer therapies. Chemplify™ has illustrated impressive results, enabling 50% faster development cycles, thrice the scalability, reduced costs by 60%, and achieving a 10-fold increase in cell expansion yield.

The funding acquired will propel the growth of ChemT's AI infrastructure, refine its AI-designed molecular products to meet Good Manufacturing Practice (GMP) standards, and scale its existing commercial partnerships effectively.

Looking Ahead

ChemT aims to transcend its initial focus on CHO and T cells, with plans to extend the capabilities of CelMo™ into other cellular systems. This includes stem cells, Natural Killer (NK) cells, and Human Embryonic Kidney (HEK) cells, all of which are integral to expanding biomanufacturing workflows intelligently.

Dr. Ling Wu, co-founder and President of ChemT, emphasizes the company's role in transforming biomanufacturing by addressing the structural challenges that have historically impeded progress. He states, “CelMo™ serves as a cellular model to discern and influence cellular activity intelligently. Our ultimate objective is to simplify the manufacturing and scaling of advanced medicines to facilitate global patient access.”

The promising trajectory of ChemT is further underscored by the validation from investors amidst a challenging financial climate for life sciences. As the demand for innovative biomanufacturing solutions continues to surge, ChemT Biotechnology remains at the forefront of this technological evolution, ready to meet the needs of pharmaceutical and biotech companies across the globe.